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Abstract Single base mutations GCA at position 663 and
GCT at position 666 of intron 6 of the human tryptophan
oxygenase gene (TDO2) are associated with a variety of
psychiatric disorders [Comings, D.E. et al. (1996) Pharmacoge-
netics 6, 307^318]. Binding of rat liver nuclear extract proteins to
synthetic double-strand oligonucleotides corresponding to three
allelic states of the region between 651 bp and 680 bp of human
TDO2 intron 6 has been studied by gel shift assay. It has been
demonstrated that to each allelic state of the region there
corresponds a specific set of proteins that interacts with it. With
the aid of computer analysis and using specific anti-YY-1
antibodies it has been shown that both mutations damage the
YY-1 transcription factor binding site.
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1. Introduction
Tryptophan 2,3-dioxygenase (TDO2, EC 1.13.11.11) is the
rate-limiting enzyme in the oxidative degradation of trypto-
phan [1], the serotonin precursor, which therefore controls
serotonin level in the body. Defects in serotonin metabolism
and abnormal serotonin/tryptophan levels have been reported
for many behavioural disorders (Tourette syndrome, attention
de¢cit hyperactivity disorder, alcoholism, depression, and
others) [2^5]. This suggests the TDO2 gene as a potential
candidate gene in psychiatric genetics. Functional variants
of this gene could account for the observed variations in
both serotonin and tryptophan levels and contribute to the
development of psychiatric disorders [4,5].
Molecular cloning and sequencing of over 9000 bp of hu-
man TDO2 DNA, which included all its exons and introns 1,
5 and 6, allowed Comings et al. to identify four polymor-
phisms of this gene and to develop genetic tests for them
[6,7]. Among them, GCA and GCT mutations 2 bp apart
in the middle of intron 6 showed a signi¢cant positive asso-
ciation with drug dependence, Tourette syndrome and atten-
tion de¢cit hyperactivity disorder [7]. Single nucleotide sub-
stitutions reported in introns are often associated with various
diseases [8^12]. However, the mechanisms by which such mu-
tations could a¡ect gene expression normally remain unclear,
unless the mutations a¡ect splicing signals. We have demon-
strated that the region between 651 and 680 bp from the start
of the intron 6 of the human TDO2 gene, in which polymor-
phic sites associated with behavioural disorders are located,
binds liver nuclear proteins, and that every allelic state the
region can be in is accounted for a speci¢c set of proteins
that interact with it. The disturbance in the binding of the
transcription factor YY-1 is one of the e¡ects of the muta-
tions.
2. Materials and methods
2.1. Oligonucleotides
Oligonucleotides corresponding to both strands of the fragment
from 651 to 680 bp of intron 6 of hTDO2 (WT) and its variants
(M1 and M2) (Fig. 1A) were kindly provided by D.E. Comings (De-
partment of Medical Genetics, Duarte, CA, USA). After annealing
the oligonucleotides were labelled with Klenow enzyme and (K-
32P)dATP and puri¢ed by gel-electrophoresis in 10% non-denaturing
PAAG.
The double-strand competing oligonucleotides were: HNF3, 5P-
cagtCGAGTTGACTAAGTCAATAATCAGAATCAGTCG-3P [13];
GATA, 5P-cagtGATCTCCGGCAACTGATAAGGATTCCCTG-3P
[14] ; HNF1, 5P-cagTGGTTAGTGTGGTTAATGATCTACAGTT-
3P [15]; C/EBP, 5P-cagtGATCCATATTAAGGACATGCCG-3P [16];
Sp1, 5P-cagtCGACTCTAGGCGGGGTTAAAGTTCT-3P [17]; AP1,
5P-cagtAGCTTGATGAGTCAGCCGGATC-3P [18]; SRE, 5P-cagtA-
CAGGATGTCCATATTAGGACATCTGCGT-3P [19] ; and ANF,
5P-cagtGCTGGTGAGATTGTGCCACAGCTCTGCA-3P [20]. The
oligonucleotides were synthesised by the H-phosphonate method
and puri¢ed by gel-electrophoresis [21].
2.2. Nuclear extract preparation and gel shift assay
Nuclear extracts from the rat liver were prepared according to
Gorski et al. [22] with the modi¢cations described in Shapiro et al.
[23]. The binding reactions with DNA were carried out in 10 Wl re-
action volume containing 1^4 Wg of nuclear extracts preincubated with
0.1^0.4 Wg calf thymus DNA at 4‡C for 10 min, 2 ng (32P)-labelled
(200^500 cps) DNA probe in a binding bu¡er (25 mM HEPES
(pH = 7.6), 80 mM KCl, 0.1 mM EDTA, 1 mM DTT, 10% glycerol).
For the competition analysis, the reaction mixture additionally con-
tained 80 ng of the corresponding unlabelled oligonucleotide. For
antibody-containing reactions, the extracts were preincubated with 1
Wl of anti-YY-1 antibody (Santa-Cruz Biotechnology, Santa-Cruz,
CA, USA) at 4‡C for 10 min. After incubation for 10 min at room
temperature the samples were analysed by electrophoretic fractiona-
tion on a 5% non-denaturing polyacrylamide gel in 0.5UTBE bu¡er
at 180 V at 4‡C. After electrophoresis gels were dried, protein DNA
complexes were visualised by autoradiography.
2.3. Recognition of transcription factor binding sites
A method based on the averaging of oligonucleotide frequencies at
each position of the functional sites of DNA was used for recognition
of these sites [24]. The initial data for the method to start working are
a set of N aligned DNA sequences of length L of the site in question
{Sn = (sn;i)}i1;L; n1;N . Oligonucleotide frequencies at each position of
the site are calculated using the following alphabets: E0 = {e01 = A,
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 5 1 3 - 6
*Corresponding author. Fax: (7) (3832) 356558.
E-mail: merkti@niboch.nsc.ru
FEBS 22946 8-11-99
FEBS 22946 FEBS Letters 00 (1999) 1^4
e02 = T, e03 = G, e04 = C}, E1 = {e11 = W = A+T, e12 = S = G+C},
E2 = {e21 = R = A+G, e22 = Y = T+C}, E3 = {e31 = M = A+C;
e32 = K = T+G}, E4 = {e41 = WW, e42 = WS, e43 = SW, e44 = SS},
E5 = {e51 = YY, e52 = YR, e53 = RY, e54 = RR} and E6 = {e61 = MM,
e62 = MK, e63 = KM, e64 = KK}:
Fepj;i  f
X
n1;N Iq1;QN sn;iqnepjg=N; 1
here: p is the alphabet number, j is the number of the oligonucleotide
in the alphabet; Q is the oligonucleotide length, 1 for E0, E1, E2, E3
or 2 for E4, E5, E6 ; N(TRUE) = 1 and N(FALSE) = 0.
For each alphabet Ep, the partial similarity Dp(S) between an arbi-
trary sequence S and the functional site in question is assessed by
frequencies F(epj;i) :
DpS  f
X
i1;L3Q1 Fepj;iUIq1;QN sn;iqnepjg3K p=L p; 2
here: ap and bp are normalising coe⁄cients calculated in accordance
with the rule: ‘mean Dp is MeanSITE(Dp) = 1 for known sites, and
MeanRAND(Dp) =31 for random DNA’. The integral estimate of
this similarity is the mean value of these partial estimates:
DS 
X
p0;6 DpS=7; 3
the recognition rule for which reads: IF {D(S)s 0} THEN {S is the
site in question}.
3. Results
We used a mobility shift assay to see if nuclear factors bind
to double-strand oligonucleotides that correspond to the dif-
ferent allelic states of the 651^680 bp region relative to start of
intron 6 of the human TDO2 gene (WT, M1 and M2 oligo-
nucleotides, Fig. 1A). Since TDO2 is a liver-speci¢c gene a rat
liver nuclear extract was used. The extract proteins formed
three complexes with the WT oligonucleotide, which corre-
sponds to the most frequent allele (Fig. 1B). Both nucleotide
substitutions found in humans [10,11] caused a dramatic
change in binding pattern. The substitution of G by A at
position 663 bp (the M1 oligonucleotide) caused the band
corresponding to complex 3 to abate, if not disappear,
abruptly and a group of less mobile bands to occur (‘complex
4’). In the case of the GCT substitution at position 666 bp
(the M2 oligonucleotide) the intensity of the indicated band
had been decreasing not so strongly, but there also appeared
new slowly migrating bands (‘complex 5’).
To answer the question as to which proteins could bind to
the WT, M1 and M2 oligonucleotides we did the search for
regions homologous to the binding sites of various transcrip-
tion factors using the TESS program package [25]. We found
regions, similar to the binding sites for the GATA; HNF1
and Sp1 transcription factor families, and to the SRE element,
to which several di¡erent factors can bind [26], and the ANF
element, whose binding factor is unknown [20]. Double-strand
oligonucleotides corresponding to such sites existing in real
genes and previously used by other investigators for the
same purposes, were synthesised and used as competitors in
gel retardation experiments. The available oligonucleotides
corresponding to the binding sites of the HNF3, C/EBP and
AP1 families of transcription factors were taken as compet-
itors.
As turns out, of the oligonucleotides used, only SRE (Fig.
2) of the mouse c-fos gene promoter (3318 to 3289) was
competing against WT: in the presence of its 40-fold excess
complex 3 would disappear. As is known, transcription fac-
tors SRF, YY-1 and NF-IL6 bind to the mouse c-fos SRE [26]
which suggests that these proteins might be candidates for
binding to the region in question. Likely involvement of tran-
scription factors YY-1 and SRF in the formation of complex
3 is also supported by the fact that the GCA transition
(oligonucleotide M1), which abruptly decreases the intensity
of band 3, occurs in a putative consensus (CCAATTT) of
SRF and YY-1 binding sites [26^29].
A further theoretical analysis of the nucleotide sequences of
the allelic states of the region in question was performed using
a method developed for averaging nucleotide and dinucleotide
frequencies at the positions of the site in question [24]. The
original data were 27 DNA fragments experimentally found to
contain the transcription factor YY-1 binding site [30]. The
fragments were aligned using the standard method of multiple
alignment maximising Gibbs potential [31]. With each posi-
tion tried for the start of the putative YY-1 site (position ‘0’
Fig. 1. Distinct nuclear proteins bind to double-strand oligonucleoti-
des comprising the sequences of three alleles of 651^680 bp region
of intron 6 of the human TDO2 gene. (A) Coding strands of oligo-
nucleotides used: WT most frequent allele, M1 and M2 mutant var-
iants. Point mutations are underlined, lowercase letters correspond
to nucleotides added to make 5P-overhangs. (B) Binding of nuclear
proteins to WT (lanes 2, 6), M1 (lanes 3, 7), M2 (lanes 4, 8) oligo-
nucleotides. Lanes 1, 5: no extract. Oligonucleotides were incubated
with 1 (L) or 4 (R) Wg of rat liver nuclear extract protein.
Fig. 2. Competition of WT oligonucleotide protein complex forma-
tion by various oligonucleotides. Lanes: 1, no extract; 2, no com-
petitor; 3^12, a 40-fold excess of unlabelled oligonucleotides: 3,
WT; 4, M1; 5, M2; 6, AP1; 7, HNF1; 8, GATA; 9, SRE; 10,
ANF; 11, AP2; 12, HNF3. Arrow denotes the position of complex
3.
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of the site), the mean nucleotide and dinucleotide frequencies
were calculated by Eqs. (2) and (3) in all positions of the
variant being analysed. The pro¢le of similarity between
YY-1 sites and WT is presented in Fig. 3A, where dotted lines
indicate the 95% boundaries of similarity with YY-1 sites
(upper) and random DNA (lower). As can be seen, the peak
of similarity between WT and YY-1 sites at position 661 is
over the upper 95% boundary, which points (arrow) at region
661^667 bp of intron 6 of the human TDO2 gene, which has a
reliable similarity with the YY-1 sites.
As turned out, the GCA (663) and GCT (666) mutations
are located within the likely YY-1 site. In the case of GCA
(663) mutation (variant M1), the similarity of the YY-1 sites
with region 661^667 bp is lower than the lower 95% boun-
dary, which implies that there is no YY-1 site in. If the muta-
tion is GCT (666), the similarity of the YY-1 sites with
variant M2 is to over the upper 95% boundary (Fig. 3B).
As can be seen, quantitatively the pattern of similarity be-
tween the YY-1 and WT (strong), M1 (none) and M2
(weak) behaves as band 3 does while the liver extracts bind
to these three variants (Fig. 1).
As to the other two transcription factors, SRF and NF-IL6,
which bind to the SRE element of the c-fos gene, [25], no
binding site has been predicted for either WT, M1 or M2 of
661^668 bp of intron 6 of the human TDO2 gene by a similar
analysis (Fig. 3). This implies that among YY-1, SRF and
NF-IL6, YY-1 is the most likely transcription factor to bind
to region 651^680 bp of intron 6 of the human TDO2 gene.
To provide an independent control, variants WT, M1, and
M2 were analysed using a program for recognising binding
sites of ten random transcription factors T3R, c-Fos, OCT,
GR, EN, RAR, GATA, MEF-2, AP-1, PR. Similar to the
results of recognition of the SRF and NF-IL6 sites, no
matches were found for the similarity patterns of ten control
sites with variants WT, M1 and M2, and WT (strong), M1
(none) and M2 (weak) band 3 in the experimental binding of
the corresponding oligonucleotides with the liver nuclear ex-
tract (Fig. 1B) and the pattern of similarity of the YY-1 sites
with these variants (Fig. 3B). Thus the control tests con¢rmed
independently that YY-1 is the most likely transcription factor
with the binding site located within 651^680 bp of human
TDO2 intron 6.
Speci¢c anti-YY-1 antibodies used in the band shift assay
gave total support to this hypothesis. As is shown in Fig. 4,
addition of antibodies to the nuclear extract totally eliminates
the protein WT oligonucleotide complex represented by band
3, which is replaced by a slower migrating band. Complex 3
also disappears in the case of oligonucleotide M2, however no
supershift can be seen, because this band is as mobile as one
of the bands of the initial pattern.
4. Discussion
Higher or lower activity of the TO enzyme in the liver could
be the cause of abnormal serotonin and tryptophan levels
observed on many behavioural disorders. With TDO2 as a
potential major candidate gene in psychiatric genetics, Com-
ings et al. screened all the exons of this gene and its 5P- and 3P-
regulatory regions for polymorphisms, but this search had
been essentially negative [6].
Over the recent years a great bulk of evidence has been
accumulated that regulatory areas of genes may be located
not only in their 5P- and 3P-regions but also within the body
of genes [32,33]. In rat TDO2 gene we have found the region
of speci¢c binding of glucocorticoid receptor extending from
the end of intron 4 to the exon G. It was shown that the
receptor binds to this region more e⁄ciently than to the 5P-
Fig. 3. Recognition of the YY-1 transcription factor binding site in
region 651^680 bp of intron 6 of human TDO2. (A) The pro¢le of
similarity between YY-1 sites and WT as calculated by Eqs. (2) and
(3). Dotted lines indicate the 95% boundaries of similarity with YY-
1 sites (upper) and random DNA (lower). The peak of similarity at
position 661, which is over the 95% boundary, points out (arrow)
the location of the potential YY-1 site in region 661^668 bp (black
rectangle). (B) Similarity of WT, M1 and M2 with YY-1, SRF and
NF-IL6 transcription factor binding sites.
Fig. 4. E¡ect of anti-YY-1 antibodies on mobility shifts of WT and
MII oligonucleotides. Lanes 1, 4: no extract. Lanes 2, 5: 3 Wg of
nuclear extract, no antibodies. Lanes 3, 6: 3 Wg of nuclear extract
was preincubated with 1 Wl of speci¢c anti-YY-1 antibodies. The po-
sitions of YY-1 containing complexes and supershift complexes (S)
are indicated on the right.
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£anking region [34] of this gene containing the known GREs
[35].
And it was the corresponding region of the human TDO2
gene that polymorphic sites, associated with such behavioural
disorders as Tourette syndrome, attention de¢cit hyperactivity
disorder and drug dependence, were found in [10]. These are
two nucleotide substitutions located much central in intron 6
(GCA at position 663 bp and GCT at position 666 bp
relative to start of the intron). In this work we have demon-
strated that the region where the mutations are located (be-
tween 651 bp and 680 bp) is the binding site for liver nuclear
extract proteins, at least part of which are transcription fac-
tors. It is conceived to be of special importance that these
mutations are responsible for a dramatic change in the set
of the proteins bound to the region. Among the changes, we
have identi¢ed the disturbance of transcription factor YY-1
binding, which is due to the destruction of its binding site.
YY-1 is a polyfunctional protein, which was shown to ei-
ther repress [33] or stimulate [34] gene expression depending
on the context of the corresponding regulatory region. As a
component of the nuclear matrix YY-1 may also be involved
in chromatin organisation possibly by tethering DNA to nu-
clear matrix [35]. Whichever it is, it in£uences transcription
intensity. Thus, both mutations damaging the YY-1 transcrip-
tion factor binding site may result in a change in TDO2 tran-
scription level, which accounts for phenotypic changes.
All together, these facts suggest that the region encompass-
ing introns 4^6 might be of regulatory importance for the
expression of the TDO2 gene; and the region in the middle
of intron 6 of the human TDO2 gene, where associations with
psychiatric disorders were found, appears to be an important
component of this regulatory region. If this is as it seems to
be, then the observed alteration in the set of the protein fac-
tors that bind to this region may have important consequen-
ces for regulation of the expression of the TDO2 gene and
may also unambiguously indicate by which mechanisms the
functional variants of the gene arise following single nucleo-
tide substitutions within its intron.
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